Our training courses are designed to help your organization to understand market access and what it ...
Read moreObtaining market access at the right time and at an appropriate price has become more complex for ph...
Read moreIntroduction of a new German Act - Strengthening Pharmaceutical Supply in the Statutory Health Insur...
Read moreEMA has published Q&A document to prepare manufacturers for the UK's withdrawal from the EU with reg...
Read moreA one stop shop for joint advice between EMA, EUnetHTA and health technology assessment bodies - the...
Read moreGiven that the UK has formally announced its decision to leave the EU, what are the implications for...
Read moreMEAs are also known by other names such as risk-sharing agreements, value-added services, and result...
Read moreThe lack of a biosimilar market in the US is largely due to the substantial patent litigations which...
Read moreThis process aims to be completely transparent , to enable faster patient access to oncology treatme...
Read moreBoth payers and physicians do not believe that at the current prices Praluent and Repatha offer sign...
Read more